UNCY News and Press, Unicycive Therapeutics Inc. From 09/07/22

Established animal model of AKI showed a statistically significant reduction of a key biomarker of kidney injury when treated with UNI-494 AKI remains a serious unmet medical need with no FDA approved drugs for its treatment On track to file regulatory submission by year end 202...

LOS ALTOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Company management will participate at the upcoming H.C. Wainwright 24 ...

LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the acceptance of two abstracts to be presented as posters and one publication...

Unicycive Therapeutics press release ( NASDAQ: UNCY ): Q2 GAAP EPS of -$0.24. As June 30, 2022, cash and cash equivalents totaled $10.6M. For further details see: Unicycive Therapeutics GAAP EPS of -$0.24

On track to file New Drug Application for Renazorb, the first proprietary nanoparticle-based phosphate binder for Chronic Kidney Disease (CKD) patients, by end of 2023 Signed first global partnership for rights to Renazorb in China with Lee’s Pharmaceutical (HK) Ltd. to f...

Hyperphosphatemia ranked as area of greatest unmet need Highlights most appealing benefits of Renazorb as efficacy/potency and lower pill burden Confirms patient preference for pills that are swallowed vs chewed LOS ALTOS, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- ...

Renazorb product profile rated as best-in-class phosphate binder Nephrologists report high prescribing intent for Renazorb pending FDA approval LOS ALTOS, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnolo...

Unicycive Therapeutics ( NASDAQ: UNCY ) granted exclusive rights to Lee's Pharmaceutical (HK) to develop, market and commercialize Renazorb in Mainland China, Hong Kong, and certain other Asian markets. Unicycive said Renazorb (lanthanum d...

Expands and accelerates Renazorb opportunity in important markets for patients with hyperphosphatemia through local partner with deep domain expertise Agreement includes upfront payment, royalties and milestone payments LOS ALTOS, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- ...

Vancouver, British Columbia--(Newsfile Corp. - June 29, 2022) - Business Television (BTV) chats with Shalabh Gupta, M.D., CEO of Unicycive Therapeutics Inc. (NASDQ: UNCY) to learn more about how they are developing life-changing new medicines to treat a variety of kidney diseases with signif...